A. Tabarroki

发表

Molecular Genetics of Myelofibrosis and its Associated Disease Phenotypes

R. Tiu, A. Tabarroki, 2014, Translational medicine @ UniSa.

Prognosis of acute renal failure in children

H. Chalian, M. Chalian, H. Otukesh, 2006, Pediatric Nephrology.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

S. Shetty, A. Advani, M. Sekeres, 2015, Clinical lymphoma, myeloma & leukemia.

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

J. Maciejewski, M. Sekeres, F. Traina, 2013, SAGE open medical case reports.

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

J. Maciejewski, R. Paquette, J. Lancet, 2012, Blood.

Immunomodulatory agents in myelofibrosis

R. Tiu, A. Tabarroki, 2012, Expert opinion on investigational drugs.

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis

L. Zhang, M. Sekeres, M. Kalaycio, 2014, Leukemia.

with higher-risk myelodysplastic syndromes Phase 2 study of the lenalidomide and azacitidine combination in patients

J. Maciejewski, R. Paquette, J. Lancet, 2013 .

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

A. Jankowska, J. Maciejewski, Y. Saunthararajah, 2013, Clinical Cancer Research.

SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype

C. O'keefe, M. Sekeres, H. Makishima, 2013, Haematologica.

Running Title: SF3B1 and non-MDS and mast cell disease

C. O'keefe, M. Sekeres, H. Makishima, 2013 .

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts

Y. Saunthararajah, M. Sekeres, H. Rogers, 2015, Leukemia & lymphoma.

Increased CDA expression / activity in males contributes to decreased cytidine analogue half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy Running title : Gender , cytidine deaminase and 5-aza / decitabine

A. Jankowska, J. Maciejewski, Y. Saunthararajah, 2012 .

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia

M. Sekeres, E. Hsi, H. Rogers, 2015, Leukemia & lymphoma.

A Prognostic Scoring System for Unclassifiable MDS and MDS/MPN

Y. Saunthararajah, M. Sekeres, F. Traina, 2012 .

Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy

H. Najmabadi, A. Tabarroki, P. Vosough, 2002 .

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation

M. Kalaycio, V. Visconte, R. Tiu, 2016, Leukemia & lymphoma.

Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine

Y. Saunthararajah, M. Sekeres, M. Kalaycio, 2014, Leukemia & lymphoma.

Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2.

M. Sekeres, M. Kalaycio, P. Elson, 2013 .

Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation

J. Maciejewski, M. Sekeres, M. Kalaycio, 2012 .

Short-term and long-term outcome of hemolytic uremic syndrome in Iranian children.

S. Fereshtehnejad, H. Otukesh, R. Hoseini, 2008, Journal of nephrology.

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

S. T. Olalla Saad, F. Costa, F. Traina, 2014, Leukemia research.

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

J. Barnard, A. Heuer, Y. Saunthararajah, 2014, Leukemia.

Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease

M. Sekeres, J. Altman, V. Visconte, 2014, Leukemia & lymphoma.

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

A. Jankowska, C. O'keefe, J. Maciejewski, 2014, Leukemia.

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations

J. Maciejewski, M. Sekeres, M. Kalaycio, 2016, American journal of hematology.

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts

J. Barnard, Y. Saunthararajah, R. Mahfouz, 2014, Journal of Hematology & Oncology.

Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib

Y. Saunthararajah, V. Visconte, R. Tiu, 2014 .

Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia

M. Kalaycio, V. Visconte, R. Tiu, 2015, Leukemia & lymphoma.

Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37)

J. Barnard, A. Heuer, Y. Saunthararajah, 2013 .

BCL-2 Family Of Genes Is a Key Regulator In The Pathogenesis Of SF3B1 Mutant and Wild Type MDS With Ring Sideroblasts and Represents a Novel Drug Target In This Disease

J. Barnard, Y. Saunthararajah, R. Mahfouz, 2013 .

Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis

J. Maciejewski, E. Hsi, V. Visconte, 2016, Leukemia & lymphoma.

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

J. Maciejewski, M. Sekeres, F. Traina, 2013, SAGE Open Medical Case Reports.

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10)

Y. Saunthararajah, S. Shetty, A. Advani, 2014, American journal of hematology.